de Iuliis F - Search Results

1

Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients.

Foglietta J, Inno A, de Iuliis F, Sini V, Duranti S, Turazza M, Tarantini L, Gori S. Foglietta J, et al. Among authors: de iuliis f. Clin Breast Cancer. 2017 Feb;17(1):11-17. doi: 10.1016/j.clbc.2016.07.003. Epub 2016 Jul 25. Clin Breast Cancer. 2017. PMID: 27561703 Review.

2

Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.

De Iuliis F, Salerno G, Corvino R, D'Aniello D, Cefalì K, Taglieri L, Lanza R, Scarpa S. De Iuliis F, et al. Clin Breast Cancer. 2017 Feb;17(1):34-40. doi: 10.1016/j.clbc.2016.06.010. Epub 2016 Jun 25. Clin Breast Cancer. 2017. PMID: 27435626

3

Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.

De Iuliis F, Salerno G, Taglieri L, De Biase L, Lanza R, Cardelli P, Scarpa S. De Iuliis F, et al. Among authors: de biase l. Tumour Biol. 2016 Mar;37(3):3379-87. doi: 10.1007/s13277-015-4183-7. Epub 2015 Oct 8. Tumour Biol. 2016. PMID: 26449821

4

On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.

De Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S. De Iuliis F, et al. Tumori. 2015 Jan-Feb;101(1):30-5. doi: 10.5301/tj.5000207. Epub 2015 Feb 5. Tumori. 2015. PMID: 25702645 Clinical Trial.

5

Taxane induced neuropathy in patients affected by breast cancer: Literature review.

De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. De Iuliis F, et al. Crit Rev Oncol Hematol. 2015 Oct;96(1):34-45. doi: 10.1016/j.critrevonc.2015.04.011. Epub 2015 May 11. Crit Rev Oncol Hematol. 2015. PMID: 26004917 Review.

6

Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.

De Iuliis F, Salerno G, Taglieri L, Scarpa S. De Iuliis F, et al. Cancer Chemother Pharmacol. 2015 Oct;76(4):679-90. doi: 10.1007/s00280-015-2818-4. Epub 2015 Jul 22. Cancer Chemother Pharmacol. 2015. PMID: 26198313 Review.

7

Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer.

De Iuliis F, Salerno G, Taglieri L, Lanza R, Cardelli P, Scarpa S. De Iuliis F, et al. Int J Biol Markers. 2017 Jul 24;32(3):e333-e336. doi: 10.5301/ijbm.5000262. Int J Biol Markers. 2017. PMID: 28430337 Free article.

8

Are we ready to change clinical practice after the 'soft and text' results?

De Iuliis F, Lanza R, Scarpa S. De Iuliis F, et al. Future Oncol. 2015;11(21):2857-60. doi: 10.2217/fon.15.202. Epub 2015 Sep 25. Future Oncol. 2015. PMID: 26403651 Review. No abstract available.

9

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.

De Iuliis F, Salerno G, Giuffrida A, Milana B, Taglieri L, Rubinacci G, Giantulli S, Terella F, Silvestri I, Scarpa S. De Iuliis F, et al. Tumour Biol. 2016 Feb;37(2):2603-11. doi: 10.1007/s13277-015-4075-x. Epub 2015 Sep 21. Tumour Biol. 2016. PMID: 26392111

10

Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.

Taglieri L, De Iuliis F, Giuffrida A, Giantulli S, Silvestri I, Scarpa S. Taglieri L, et al. Among authors: de iuliis f. Oncol Lett. 2017 Sep;14(3):3832-3838. doi: 10.3892/ol.2017.6597. Epub 2017 Jul 18. Oncol Lett. 2017. Retraction in: Oncol Lett. 2023 Jul 03;26(2):352. doi: 10.3892/ol.2023.13938. PMID: 28927154 Free PMC article. Retracted.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters